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Summary An antigen of apparent molecular weight of 24000, reactive with a murine monoclonal antibody, has been isolated from a
cachexia-inducing tumour (MAC 16) and has been shown to initiate muscle protein degradation in vitro using isolated soleus muscle.
Administration of this material to female NMRI mice (20g) produced a pronounced depression in body weight (2.72 ± 0.14 g; P<0.005 from
control) over a 24 h period. This weight loss was attenuated in mice pretreated with the monoclonal antibody (0.06 + 0.26 g over 24 h) and
occurred without a reduction in food and water intake. There was no change in body water composition, and the major contribution to the
decrease in body weight was a decrease in the non-fat carcass dry weight (mainly lean body mass). The plasma levels of glucose and most
amino acids were also significantly depressed. The decrease in lean body mass was accounted for by an increase (by 50%) in protein
degradation and a decrease (by 50%) in protein synthesis in gastrocnemius muscle. Protein degradation was significantly decreased and
protein synthesis increased to control values in mice pretreated with the monoclonal antibody. Protein degradation initiated in vitro with the
proteolysis-inducing factor was abolished in mice pretreated with eicosapentaenoic acid (EPA), which had been shown to prevent muscle
wastage in mice bearing the MAC16 tumour. Protein degradation was associated with a significant elevation of prostaglandin E2 production
by isolated soleus muscle, which was inhibited by both the monoclonal antibody and EPA. These results suggest that this material may be the
humoral factor mediating changes in skeletal muscle protein homeostasis during the process of cancer cachexia in animals bearing the
MAC16 tumour, and could potentially be involved in other cases of cachexia.
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Cachexia is the most common adverse systemic effect of malig-
nancy, affecting up to 50% of all untreated cancer patients and is
an important determinant in their overall survival (De Wys et al,
1980). Loss ofadipose tissue and particularly skeletal muscle mass
during the process ofcachexia leads to weakness and an increased
susceptibility to infection, with a 30% loss in body weight proving
fatal (Brennan, 1977). In cancer cachexia weight loss arises
equally from muscle and fat, in contrast to starvation, in which
case three-quarters of the weight is lost from fat and only a small
amount from muscle (Cohn et al, 1981). Thus, for a given degree
ofweight loss, there is more wasting ofmuscle in a cancer patient
than in a normal subject. Body composition analysis of patients
with cancer and those with anorexia nervosa using 40K counting
have shown that the former lose a greater proportion of body cell
mass, even though the total body weight loss may be only one-half
ofthat ofpatients with anorexia (Moley et al, 1987). Although the
total skeletal muscle mass decreases during the process of
cachexia, loss of white muscle exceeds that of red muscle (Clark
and Goodlad, 1971). Wasting of peripheral muscle may be due to
increased muscle catabolism or decreased protein synthesis, or a
combination of the two. A decrease in protein synthesis has been
observed in human rectus abdominis muscle from cancer patients
when compared with age-matched control subjects (Lundholm
et al, 1976). In patients with hepatocellular carcinoma, the high
protein turnover rates were found to be due to elevated protein
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breakdown and oxidation ofamino acids (O'Keefe etal, 1990). As
loss ofmuscle often precedes a fall in food intake (Costa, 1963), a
number ofstudies have been directed towards the identification of
the factor responsible for changes in protein balance in skeletal
muscle.
Several factors have been suggested as signals for the increased
muscle proteolysis including tumour necrosis factor alpha (TNF-
a) and interleukin 1 (IL-1) and 6 (IL-6). In vivo studies have
shown muscle proteolysis to be significantly increased by TNF-a
and synergistically increased when combined with IL-1,B (Flores
et al., 1989). However, Goldberg et al (1988) were unable to detect
a catabolic effect of TNF-a, IL-la or IL-1, singly, or together,
after incubation of skeletal muscle in vitro, suggesting that the
effects of the cytokines on protein balance in skeletal muscle may
be triggered by an intermediatory unknown factor. This appears
not to be IL-6 as recombinant human material did not affect either
the rate ofprotein synthesis or stimulate protein breakdown in rat
skeletal muscle (Garcia-Martinez et al., 1994).
Our own studies using the MAC16 murine cachexia model have
also provided evidence for a proteolysis-inducing factor in the
serum of animals with weight loss (Smith and Tisdale, 1993a).
This material has been shown to be aproteoglycan or glycoprotein
ofapparent molecular weight of24 000, which is present not only
in the MAC16 tumour, but also in the urine of cachectic cancer
patients (Todorov et al, 1996a). The material produced a state of
cachexia when administered to non-tumour-bearing animals and
was capable ofinducing a catabolic state in gastrocnemius muscle
in vitro (Todorov et al, 1996b). The present report provides further
information on the effect of this material on skeletal muscle
protein homeostasis both in vitro and in vivo.
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Figure 1 Dose-response relationship for the induction of tyrosine release
from soleus muscle in vitro using affinity purified proteolysis-inducing factor
from the MACI 6 tumour. Final values were obtained by subtracting basal
values from the total tyrosine released and are given as the mean ± s.e.m.
for six determinations per value. Differences from control values were
determined by Student's t-test and are indicated as bpC 0.01
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Figure 2 Disappearance of '251-labelled HPLC-purified proteolysis-inducing
factor from the blood of female NMRI mice bearing the MAC16 tumour. The
material was administered i.v. in PBS and the level of radioactivity in the
blood was determined from samples obtained from the tail vein
MATERIALS AND METHODS
Animals
Pure strain NMRI mice were obtained from our own breeding
colony and were fed a rat and mouse breeding diet (Pilsburys,
Birmingham, UK) and water ad libitum. Fragments ofthe MAC16
tumour excised from donor animals with established weight loss
were implanted into the flanks ofNMRI mice by means of a trocar
as described (Beck and Tisdale, 1987). Tumours were excised
from mice with weight loss between 20 and 25% and used to
prepare the proteolysis inducing factor.
Table 1 Retention of radioactivity and excretion pattern 24 h after
administration of 1251-labelled proteolysis-inducing factor
Organ Per cent of original (± s.e.m.)
Retention
Tumour 0.9 ± 0.5
Gastrointestinal tract 0.8 ± 0.2
Lungs 0.16 ± 0.03
Liver 0.46 ± 0.1
Kidney 0.16 ± 0.01
Spleen 0.16 ± 0.05
Heart 0.13 ± 0.01
Excretion
Urine 37 ± 9
Faeces 0.3± 0.03
acetonitrile in water gradient as described by Todorov et al.
(1996a,b). The acetonitrile was removed from the samples under a
stream of nitrogen. To prepare the labelled sample, material
eluting from the C8 column at 55% acetonitrile was dialysed
against water in a final volume of 200 ,u and iodinated using
Na125I (0.1 mCi, sp. act. 17.4 mCi ,ug-', Amersham, UK) and the
catalyst N-chlorobenzene sulphonamide immobilized on plastic
beads (lodobeads; Pierce, Rockford, IL, USA). After a 15 min
incubation at 20°C, the reaction was terminated by removal ofthe
beads, and 0.5 ml of0.5 M potassium iodide was added. The solu-
tion was passed through a Sephadex G-25 column equilibrated
with 0.1% bovine serum albumin and 4M urea in phasphate-
buffered saline (PBS). Fractions (300 pl) were collected and the
radioactive fractions from the first peak were concentrated against
water using an Amicon filtration cell containing a membrane filter
with a molecular weight cut-offof 10 000.
Protein synthesis and degradation in gastrocnemius
muscle
Mice were administered 0.25 ml ofphysiological salinecontaining
0.4 mM L-[4--3H]phenylalanine (sp. act. 156 mCi mmol-') by i.p.
injection together with i.v. injections of purified proteolysis-
inducing factor (4 x 150gl) at 1.5 h intervals. Forprotein degrada-
tion, animals were administered L-[4--3H]phenylalanine 24 h
before the proteolysis-inducing factor. Protein synthesis and
degradation were determined as described previously (Beck et al,
1991). The rate ofprotein synthesis was calculatedby dividing the
amount of protein-bound radioactivity by the amount of acid-
soluble radioactivity, and the rate of protein degradation was
calculated by dividing the amount of [3H]phenylalanine radio-
activity released into the incubation medium by the specific
radioactivity ofprotein-bound [3H]phenylalanine.
Purification of proteolysis-inducing factor
Solid MAC16 tumours were homogenized followed by ammo-
nium sulphate (40%, w/v) precipitation, and the supematant was
subjected to affinity chromatography using a monoclonal antibody
purified as described previously (Todorov et al., 1996b). The
immunogenic fractions were subject to hydrophobic chromatog-
raphy using a Brownlee Aquopore RP-300 C8 column using an
Body composition analysis
Each carcass was placed in an oven at 800C until constant weight
was reached. Carcasses were then reweighed and the total fat
content was determined by the method of Lundholm et al (1980).
The residue was the non-fat mass. The water content was calcu-
lated from the wet and dry weights.
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Table 2 Effect of affinity-purified MAC16 tumour extract on body weight loss, body composition and plasma metabolite levels in female NMRI mice 24 h after
treatmenta
Group Weight loss Dry weight Fat Water Food intake Water intake Glucose Triglyceride Fatty acid
(g) (g) (g) (%) (g day-1) (ml day-1) (mg 100 ml-') (mg 100 ml-') (mM)
Control 0.043± 0.11 7.0 ± 0.4 1.4 ± 0.3 63.2 ± 0.4 2.5 2.8 225± 11 87±9 0.47± 0.05
Antigenb 2.72d ± 0.14 6.1 ± 0.4e 1.0 ± 0.1 62.1 ± 0.9 3.3 2.8 152 ± 7' 86± 19 0.57± 0.03
Antigen + Abc 0.06 ± 0.26 7.4 ± 0.4 1.3 ± 0.4 64.1 ±0.4 2.4 2.9 175± 15 86± 11 0.44± 0.08
aAII values are given as means ± s.e.m. forfive animals per group. The initial weight of the mice was 20.5 ± 1.2 g. Immunoreactive material was concentrated
with an Amicon filtration cell containing a membrane filter with a molecular weight cut-off of 3000 against phosphate-buffered saline (PBS). The concentrate was
resuspended in PBS and portions (7 gg) were injected into the tail vein of five female NMRI mice (four injections at 1.5 h intervals). Monoclonal antibody (0.8 mg
protein in 350 RI PBS by i.p. injection) was administered 24 h before the first injection of the affinity-purified material. Body composition analysis was performed
as described previously (Smith and Tisdale, 1993a). Glucose and triglyceride were measured by quantitative enzymatic determination (Sigma Diagnostics,
Poole, UK) and fatty acids by a kit purchased from Wako Chemicals, Neuss, Germany. bAffinity-purified MAC16 tumour extract. cAffinity-purified MAC tumour
extract and monoclonal antibody. dp= 0.005 from the control group. eP = 0.05 from group administered monoclonal antibody. 'P= 0.01 from control group.
Table 3 Plasma concentrations of amino acids, 24 h after administration of
PBS (C) or proteolysis-inducing factor (T)
Amino acid Concentration (nmole ml-1)
C T
Asp 17.7±4.3 13.0±2.5
Thr 200 ± 10 157± 7a
Ser 160±0 127±7a
Glu+Asp 170±98 117±3
Gln 413 ± 40 313± 12
Pro 130±6 66±lb
Gly 263 ± 13 200±10a
Ala 630 ± 45 370± 10a
Cys 2.5±0.3 1.5±0.9
Met 57 ± 1.5 41 ± 0.9$
Iso 95 ±5 69± 5a
Leu 147±6 107±3a
Tyr 58±0.7 53±4
Phe 83±6 72±2
Lys 320 ± 12 247± 15a
Trp 110±0 95±3a
His 69±2 48±2c
Arg 22 ± 18 106 ± 29
Results are expressed as means ± s.e.m. for four animals per group and
differences from the control group were determined by Student's t-test and
are indicated as ap< 0.05, bp< 0.01 and c P < 0.005.
Tyrosine release assay
Mice were injected i.v. with the proteolysis-inducing factor as
described in the figure legends, and after 24 h the soleus muscles
were ligated by the tendons, dissected out intact and placed in ice-
cold isotonic saline. They were then quickly ligated to stainless-
steel supports under slight tension, which resembled that observed
at resting length in vivo, and incubated for 2 h in Krebs-Henseleit
buffer containing 6mM D-glucose, 1.2 mg ml-' bovine serum
albumin and 130gg ml' cycloheximide with continuous gassing.
At the end of the incubation, the buffer was removed, de-
proteinized with ice-cold 30% trichloroacetic acid (0.2 ml),
centrifuged at 2800g for 10 min and the supernatant was used for
the measurement of tyrosine by a fluorimetric method (Waalkes
and Udenfriend, 1957) at 570 nm on a Perkin-Elmer LS-5 lumi-
nescence spectrometer. Tyrosine is present in most proteins and is
neither synthesized nor metabolized by skeletal muscle and there-
fore gives a reasonable estimate of total protein degradation.
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Figure 3 Effect of the proteolysis-inducing factor (p24) on the rates of
protein synthesis (E2) and degradation (O) in gastrocnemius muscle 24 h
after in vivo administration according to the protocol described in the legend
to Table 2. One group of mice was pretreated with the monoclonal antibody
(Ab) (0.8 mg protein) 24 h before the administration of the factor whereas the
control group received PBS. Results are expressed as means + s.e.m. for
four animals per group. In the treated group, differences from the control
group were determined by Student's t-test and are indicated as a P 0.05
whereas in the antibody group differences from the treated group are
indicated as a P< 0.05 and b P< 0.01
However, it does not distinguish between the breakdown of total
and myofibrillar proteins.
Prostaglandin E2 determination
The soleus muscles were removed from NMRI female mice 24 h
after the first injection ofthe proteolysis-inducing factor and incu-
bated for 2 h in Krebs-Henseleit buffer as for tyrosine release. For
in vitro studies, muscles were preincubated for 30 min in RPMI-
1640 medium without phenol red containing normal mouse serum
(7%) with or without the proteolysis-inducing factor. The muscles
were rinsed three times, the medium replaced by Krebs buffer and
the incubation was continuedforafurther 1.5 h. Aportion (100R1)
of the soleus muscle incubation medium was mixed with
[5,6,8,11,12,14,15-3H(N)]-prostaglandin E2 (0.1 ,Ci; sp. act
154 Ci mmol-') (Amersham, UK) and PGE2 rabbit antiserum
(Sigma Chemical, Poole, Dorset, UK) (for the particular batch a
1:20 dilution was used to give 40% binding of [3H]-PGE2 in 100 ul)
in Eppendorftubes, vortexed andincubatedfor 1 hat 37°C. Samples
were then kept at 4°C for 5 min and a mixture of ice-cold dextran
charcoal (500gl) was added and allowed to stand for 15 min at4°C.
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Table 4 Distribution of L-[4-3H] phenylalanine in tissues 24 h after
administration of proteolysis-inducing factor
Tissue Treatment Radioactivity (d.p.m. per g wet tissue)
Acid insoluble Acid soluble
Control 76478 ± 9826 16849 ± 1392
Gastrocnemius p24 43250±5122a 16718 ±501
muscle Ab 88194 ± 8523 15631 ± 810
Control 447407 ± 138371 553229 ± 79738
Heart p24 615217 ±136344 695900 ±54183
Ab 573900 ± 132468 555711± 46025
Control 785751 ± 158151 359177 ± 38695
Liver p24 1083819 ± 271086 386490 ± 28803
Ab 831131± 69808 337540 ±16574
Control 578175 ± 106023 431939 ± 42523
Spleen p24 1136278 ±329002 661783± 51711 a
Ab 984339 ± 291984 536050 ± 53421
Control 703433 ± 183645 431565 ± 56658
Kidney p24 598577 ± 270362 490861 ± 17929
Ab 762070 ± 120617 428476 ± 16323
Results are expressed as means ± s.e.m. for four animals per group and
differences from the control group were determined by Student's t-test and
are indicated as ap< 0.05.
Bound and unbound material were separated by centrifugation
(2000gfor 10 min at4°C) andthe concentration ofPGE2 was deter-
mined from standard curves prepared on the same day.
Determination of plasma amino acid levels
Blood was removed from animals, using a heparinized syringe, by
cardiac puncture, under anaesthesia with a mixture of halothane,
oxygen and nitrous oxide. Plasma was prepared by centrifuging
whole blood in a Beckman microfuge for 30 s and amino acid
profiles were obtained by Alta Bioscience, University of
Birmingham, UK.
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Figure 4 (A) Induction of tyrosine release ex vivo in soleus muscle 24 h
after administration of proteolysis-inducing factor alone (-) or after
pretreatment with monoclonal antibody (O) administered according to the
protocol described in the legend to Table 2. Values for control muscles have
been subtracted from the values shown, which are means ± s.e.m. for four
animals per group. (B). Induction of PGE2 release ex vivo from soleus
muscles from mice treated with proteolysis-inducing factor alone (U) or
pretreated with the monoclonal antibody (L). Values for control muscles have
been subtracted from the values shown, which are means ± s.e.m. for four
animals per group. Differences from controls as determined by Student's t-
test are shown as b P < 0.01. Differences between antibody treated and non-
treated are indicated as ap < 0.05 and bp< 0.01
RESULTS
Affinity chromatography of an extract of the MAC16 tumour
yielded material containing two immunoreactive bands of
apparent molecular weights of 69 000 and 24 000, as reported
previously (Todorov et al. 1996a), which could be further fraction-
ated by reversed-phase high performance liquid chromatography
(HPLC). The material of molecular weight 24 000 appears to be a
proteoglycan or sulphated glycoprotein (Todorov et al., 1996a)
that binds tightly to mouse albumin to form a complex ofapparent
molecular weight 69 000. The material was capable of direct
induction of protein degradation in isolated soleus muscle as
measured by tryrosine release (Figure 1). High concentrations of
the material were inhibitory to protein degradation, resulting in a
bell-shaped dose-response curve similar to that observed with
serum from mice bearing the MAC16 tumour and increasing
weight loss (Smith and Tisdale, 1993b).
To determine the pharmacokinetics of the material of apparent
molecular weight 24 000 before in vivo administration, HPLC-
purified antigen was labelled with 1251 and the labelled material
was administered i.v. to female NMRI mice bearing the MAC16
tumour (Figure 2). There was a rapid disappearance of label from
the blood (t12 of a phase, 36 min), followed by a second slower
elimination rate (t12 of 3 phase, 25.3 h). Most of the radioactivity
(37%) appeared in the urine within the first 24 h, with only a small
amount (0.3%) in faeces and less than 3% being retained by the
individual organs and tumour (Table 1). In view ofthe rapid elim-
ination rate, antigen was administered to non-tumour-bearing mice
at 1.5-h intervals (four doses over a 6 h period) and the effect on
body weight and body composition was determined.
The results presented in Table 2 show a significant decrease in
body weight in mice receiving antigen, which was attenuated by
prior administration of the monoclonal antibody. There was no
reduction in food or water intake associated with the weight loss
(Table 2). Body composition analysis showed a significant reduc-
tion in the carcass dry weight without a change in body water
composition. Carcass dry weight was increased up to control
values in mice pretreated with the monoclonal antibody. Blood
glucose levels were also decreased (Table 2). In addition, there
was a significantdecrease in the plasma levels ofthreonine, serine,
proline, glycine, alanine, methionine, isoleucine, leucine, lysine,
tryptophan and histidine (Table 3).
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Despite this decrease in plasma amino acid levels, there was an
increase (by 50%) in protein degradation and a decrease (by 50%)
in protein synthesis in gastrocnemius muscle 24 h after the admin-
istration of the antigen as determined by L-[4-3H]phenylalanine
labelling (Figure 3 and Table 4). Protein degradation was signifi-
cantly decreased and protein synthesis increased in mice pretreated
with the monoclonal antibody such that the values were not signif-
icantly different from the control group. The effect of the antigen
on protein synthesis in heart, kidney, spleen and liver is shown in
Table 4. There was no significant depression in protein synthesis in
other host organs at dose levels that produced a profound depres-
sion of protein synthesis in skeletal muscle. In fact, in heart, liver
and spleen there was a tendency for an increase in protein
synthesis, but this did not reach significant levels. There was no
effect on the acid soluble pool of [3H]phenylalanine except in
spleen, where there was a significant elevation in the presence of
antigen (Table 4). Protein degradation was also significantly
elevated in soleus muscle 24 h after antigen administration as
measured by tyrosine release (Figure 4A) and this effect was atten-
uated in mice pretreated with the monoclonal antibody. Induction
of protein degradation in soleus muscle was accompanied by a
significant elevation ofprostaglandin E2 (PGE2) production during
the incubation period, which was completely inhibited in mice
pretreated with the monoclonal antibody (Figure 4B). An
increased tyrosine release was not seen in muscles isolated from
mice previously dosed for 24 h with the polyunsaturated fatty acid,
eicosapentaenoic acid (EPA) (Figure SA). The increase in protein
degradation was again accompanied by an elevation of PGE2,
which was reduced down to control values in muscles from mice
treated with EPA (Figure SB). This suggests that PGE2 may be the
intracellular mediator of the induction of proteolysis by the
material of apparent molecular weight 24 000.
DISCUSSION
This study shows that a material of apparent molecular weight
24 000 isolated from a cachexia-inducing tumour (MAC16), when
administered to non-tumour-bearing mice, induces a state of
cachexia similar to thatproduced by the tumour (Beck and Tisdale,
1987). The major compartment of weight loss is lean body mass
and this is due to an inhibition ofprotein synthesis and an increase
in protein degradation in skeletal muscle. Previous studies have
shown a depression in protein synthesis and an increase in protein
degradation in skeletal muscle ofmice bearing the MAC16 tumour
(Beck et al, 1991). Unlike the effect of the cytokines TNFa, IL-1
and IL-6 the material of molecular weight 24 000 was not only
capable of increasing protein degradation after administration in
vivo, but also caused protein degradation in vitro, using isolated
whole muscle. This suggests a direct effect of this material on
skeletal muscle protein homeostasis.
We have previously shown a rise in the PGE2 level of gastroc-
nemius muscle after incubation with serum from cachectic mice
bearing the MAC16 tumour, conditions that lead to an elevated
protein degradation (Smith and Tisdale, 1993b). Induction of
muscle protein degradation by the proteolysis-inducing factor was
also associated with a rise in muscle PGE2 production. This
appeared to be causally related to the process, as inhibition of
protein degradation by an antibody to the proteolysis-inducing
factor or by pretreatment of the mice with EPA, which has been
shown to reduce protein degradation in mice bearing the MAC16
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Figure 5 Inhibition of tyrosine release (A) and PGE2 release (B) in isolated
gastrocnemius muscle induced by the proteolysis-inducing factor (0.026
ELISA units) by EPA. Control mice (U) received liquid paraffin (100 RI) while
the other group (O) were treated orally with a single dose of EPA (50 mg;
kindly donated by Dr D Horrobin, Scotia Pharmaceuticals, UK) in liquid
paraffin (50 ,ul). After 24 h muscles were excised and used for the experiment
as described in Materials and methods. Values for muscles that were
incubated with mouse serum alone have been subtracted from the values
shown, which are given as means ± s.e.m. Differences between the EPA
treated and non-treated groups are indicated as b P < 0.01
tumour (Beck et al., 1991), caused an inhibition of PGE2 produc-
tion. These results suggest that PGE2 may be the intracellular
mediator of the proteolytic process induced by the proteolysis-
inducing factor. The role ofPGE2 in muscle protein degradation is
controversial. Thus Rodemann and Goldberg (1982) were the first
to show that PGE2 and arachidonic acid were able to stimulate
protein degradation in isolated rat skeletal and atrial muscle. Other
studies have shown PGF2a to activate synthesis of muscle proteins
(Reeds et al, 1985) and arachidonate to stimulate (Palmer and
Wahle, 1987) or inhibit protein synthesis (Rotman et al, 1985),
without affecting protein degradation. Some studies suggest that
TNFa alone, or in combination with IL-1 (Flores et al, 1989;
Hellerstein et al, 1989), increases protein degradation through a
prostaglandin intermediate in vivo. Experiments using the Yoshida
ascites hepatoma, a tumour associated with a marked activation of
muscle protein degradation, show that administration ofinhibitors
of prostaglandin synthesis including naproxin (Strelkov et al,
1989) and acetylsalicylic acid (Tessitore et al, 1994) also inhibit
the elevated muscle catabolism. However, the role of PGE2 in
muscle protein degradation has remained controversial (Palmer,
1990). In particular, arachidonate or PGE2 has not been shown to
affect total or myofibrillar protein degradation under a variety of
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conditions in vitro and the cyclo-oxygenase inhibitor
indomethacin does not affect protein degradation in septic rats in
vivo (Hasselgren et al, 1990). Thus, the role ofPGE2 in the signal
transduction pathways involved in protein degradation requires
further studies.
Despite the extensive loss of lean body mass 24 h after in vivo
administration of the proteolysis-inducing factor, plasma levels of
threonine, serine, proline, glycine, alanine, methionine, isoleucine,
leucine, lysine, trypophan, histidine and glucose were found to be
decreased. We have previously reported decreased serum levels of
threonine, serine, glycine, alanine, valine, isoleucine, leucine,
lysine, methionine, tyrosine, histidine (Beck and Tisdale, 1989)
and glucose (McDevitt and Tisdale, 1992) in cachectic mice
bearing the MAC16 tumour. Most investigators have also noted
widespread decreases in plasma levels of free amino acids in
patients with cachexia. Thus, a study of Norton et al (1985) of
patients with oesophageal carcinoma and with 22% weight loss
showed decreased fasting plasma levels of threonine, serine,
proline, glycine, alanine, tyrosine, phenylalanine, lysine, histidine,
arginine and aspartate. Another study of weight-losing cancer
patients with about 7% weight loss showed decreased alanine,
glutamate, threonine, serine, proline and histidine (Clarke et al,
1978). The reason for this apparent anomaly is unknown, but it
could result from an increased utilization of amino acids or an
increased elimination in the urine.
Previous studies have reported a depression ofprotein synthesis
in skeletal muscle after implantation ofthe Ehrlich ascites tumour,
which was not a consequence ofthe metabolic demands, providing
evidence for the production of a humoral factor by the tumour
(Lopes et al, 1989). The present study has shown a proteolysis-
inducing factor to be capable of inhibiting protein synthesis in
skeletal muscle and this, together with the increase in protein
degradation, provides evidence that it is the humoral factor associ-
ated with cancer cachexia.
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